Nanobiotix SA, which has discovered a way of enhancing the effects of radiation treatment on cancer, has appointed Alain Dostie as its chief operating officer. Mr Dostie previously was general manager for oncology in Germany for Novartis. He will lead the commercialisation of the company’s lead nanomedicine product, which is expected to receive European approval as a medical device in 2017.
Nanobiotix announced the appointment on 7 February 2017.
Copyright 2017 Evernow Publishing Ltd